tga bpc-157 approval status Therapeutic Goods Administration issues safety alert amid explosion of illegal peptide use Peptides, Influencers and the Importance

Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively

F.TengY

has advocated for deregulating a number of peptides, but scientists at the Food and Drug Administration say theres insufficient evidence to recommend their use

12 Another key area of regulatory focus in FY25 compared to prior years includes the crackdown on promotional communications